Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Recruiting 3Terminated 1

Sponsor Class

OTHER 8INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1

Conditions

Stomach Neoplasms 1Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × SHR-1701 × 1 year × Clear all
NCT05671822 2026-02-12

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2 Recruiting
258 enrolled
Gastrointestinal

HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

NCT07175220 2025-11-18

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07102901 2025-09-10

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
351 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05149807 2025-08-20

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2/3 Terminated
81 enrolled
Gastrointestinal

Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡